Natalie Dayan

Dr. Natalie Dayan


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Hypertension
Verified
Journal Article
Closed access
PDF file
SGSophie Grand’mAison
Sophie Grand’mAison
LPLouise Pilote
Louise Pilote
MOMarisa Okano
Marisa Okano
TLTara Landry
Tara Landry
NDNatalie Dayan
Natalie Dayan
Women with prior hypertensive disorders of pregnancy (HDP) are at twice the risk of cardiovascular disease compared with women with prior normotensive pregnancy, possibly because of sustained vascular dysfunction after delivery. The aim of this systematic review and meta-analysis is to summarize evidence of vascular dysfunction at least 3 months after HDP. Articles in all languages were retrieved from principal databases. Studies included were observational, with HDP as the main exposure and measurements of vascular dysfunction via imaging modalities or serum biomarkers as the main outcome, assessed at least 3 months postpartum. We pooled results of modalities reported in >3 studies using a random effects model. Of 6109 potentially relevant studies, 72 were included that evaluated 10 imaging modalities and 11 serum biomarkers in 8702 women. There was evidence of vascular dysfunction in women post HDP compared with women with prior normal pregnancy when measured by carotid-femoral pulse wave velocity (0.64 m/s [0.17–1.11]), carotid intima–media thickness (0.025 mm [0.004–0.045]), and augmentation index (5.48% [1.58–9.37]), as well as mean levels of soluble fms-like tyrosine kinase (6.12 pg/mL [1.91–10.33]). Between-groups differences in measures of vascular dysfunction were more pronounced when assessments were performed in younger women (<40 years) or closer to the index pregnancy for almost all modalities. In conclusion, pooled data from studies evaluating vascular imaging suggest that some vascular dysfunction persists after HDP as compared with women with prior normal pregnancy.

1 September 2017 in JACC
Verified
Journal Article
Closed access
NDNatalie Dayan
Natalie Dayan
KFKristian B. Filion
Kristian B. Filion
MOMarisa Okano
Marisa Okano
CKCaitlin Kilmartin
Caitlin Kilmartin
SRShauna Reinblatt
Shauna Reinblatt
JUJacob A. Udell
Jacob A. Udell

3 February 2019 in Canadian Medical Association Journal
Verified
Journal Article
Closed access
PDF file
NDNatalie Dayan
Natalie Dayan
KJK.S. Joseph
K.S. Joseph
DFDeshayne B. Fell
Deshayne B. Fell
CLCarl A. Laskin
Carl A. Laskin
OBOlga Basso
Olga Basso
JRJoel G. Ray
Joel G. Ray
BACKGROUND: The extent to which infertility treatment predicts severe maternal morbidity is not well known. We examined the association between infertility treatment and severe maternal morbidity in pregnancy and the postpartum period. METHODS: We conducted a cohort study using population-based registries from Ontario between 2006 and 2012. Pregnancies achieved using infertility treatment (ovulation induction, intrauterine insemination or in vitro fertilization with or without intracytoplasmic sperm injection) were compared with unassisted pregnancies using propensity score matching, based on demographic, reproductive and obstetric factors. The primary outcome was a validated composite of severe maternal morbidity or maternal death from 20 weeks’ gestation to 42 days postpartum. We also calculated the odds ratio of a woman having 1, 2, or 3 or more severe maternal morbidity indicators in relation to invasive (e.g., in vitro fertilization) or noninvasive (e.g., intrauterine insemination) infertility treatment. RESULTS: We matched 11 546 infertility treatment pregnancies with 47 553 untreated pregnancies. Severe maternal morbidity or maternal death occurred in 356 infertility-treated pregnancies (30.8 per 1000 deliveries) versus 1054 untreated pregnancies (22.2 per 1000 deliveries); relative risk 1.39 (95% confidence interval [CI] 1.23–1.56). The likelihood of a woman having 3 or more severe maternal morbidity indicators was increased in women who received invasive infertility treatment (odds ratio [OR] 2.28, 95% CI 1.56–3.33) but not in those who received noninvasive infertility treatment (OR 0.99, 95% CI 0.57–1.72). INTERPRETATION: Women who undergo infertility treatment, particularly in vitro fertilization, are at somewhat higher risk of severe maternal morbidity or death. Efforts are needed to identify patient- and treatment-specific predictors of severe maternal morbidity that may influence the type of treatment a woman is offered.

1 December 2021 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
JSJulia Smith
Julia Smith
MVMaria P. Velez
Maria P. Velez
NDNatalie Dayan
Natalie Dayan

8 October 2014 in Obesity
Verified
Journal Article
Open access
PDF file
NDNatalie Dayan
Natalie Dayan
LPLouise Pilote
Louise Pilote
LOLucie Opatrny
Lucie Opatrny
OBOlga Basso
Olga Basso
CMCarmen Messerlian
Carmen Messerlian
SDStella S. Daskalopoulou
Stella S. Daskalopoulou
Objectives: Overweight and obese women may be heavy users of in vitro fertilization (IVF) owing to obesity‐related oligo‐anovulation. The higher doses of gonadotropins required to achieve pregnancy in obese women may contribute to impaired placentation and the development of preeclampsia. This study was designed to assess the combined effect of high maternal body mass index (BMI) and IVF on risk of preeclampsia and to evaluate for an interaction between the two factors.Methods: This is a hospital‐based cohort study of 10,013 singleton pregnancies that delivered from 2001 to 2008 at a tertiary hospital in Montreal, Canada. The combined effect of high BMI and IVF on preeclampsia versus no risk factors was estimated in multivariate logistic regression models fitted with an interaction term between high BMI (> 25 or > 30 kg/m2) and IVF.Results: IVF pregnancies in obese women had a considerably higher risk of preeclampsia than spontaneous nonobese pregnancies (OR 6.7, 95% CI 3.3‐13.8; p interaction 0.03). IVF was not independently associated with preeclampsia (OR 0.6, 95% CI 0.3‐1.4). Analyses were similar in subgroup analyses and in analyses correcting for bias.Conclusions: High BMI is strongly associated with preeclampsia, and this risk is compounded in IVF pregnancies.

1 April 2016 in Fertility and Sterility
Verified
Journal Article
Closed access
NDNatalie Dayan
Natalie Dayan
ALAndrea Lanes
Andrea Lanes
MWMark C. Walker
Mark C. Walker
KSKaren A. Spitzer
Karen A. Spitzer
CLCarl A. Laskin
Carl A. Laskin